Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line
PR99964
SAN DIEGO, April 19, 2023 /PRNewswire=KYODO JBN/ --
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of
biopharmaceutical contract development and manufacturing services, is pleased
to announce that the United States Food and Drug Administration (FDA) has
approved the company's high potency vial line to manufacture a commercial
product.
Logo - https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg
"Receiving FDA approval on our HPAPI fill line is an exciting milestone for our
company, and couldn't have happened without the hard work, hours of
preparation, diligence and support from the Aji Bio-Pharma team across our
whole organization. As a leading global CDMO, we are dedicated to providing
high-quality drug process development and manufacturing services to
biotechnology and pharmaceutical companies worldwide." said Bert Barbosa,
President & COO, Ajinomoto Bio Pharma Services, US.
Aji Bio-Pharma has six fill finish lines located in San Diego, including a new
line that offers a range of configurations, including prefilled syringes,
cartridges and vials. The high-speed process is rated to move up to 22,000
syringes per hour through the line, with a batch capacity of over 200 thousand
syringes. This multi-purpose fill line has been designed to meet FDA and EMEA
commercial compliance.
About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and
manufacturing organization with sites in Belgium, United States, Japan, and
India, providing comprehensive development, cGMP API manufacturing, and aseptic
fill finish services for small and large molecule APIs and intermediates.
Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and
capabilities for pre-clinical and pilot programs to commercial quantities,
including high potency APIs (HPAPI), continuous flow manufacturing,
oligonucleotide synthesis, biocatalysis, Corynex(R) protein expression
technology, antibody drug conjugations (ADC) and more. Ajinomoto Bio-Pharma
Services is dedicated to providing a high level of quality and service to meet
our client's needs. Learn more: www.AjiBio-Pharma.com
SOURCE: Ajinomoto Bio-Pharma Services
CONTACT: info@us.ajibio-pharma.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。